476472-35-2Relevant academic research and scientific papers
MIXED LINEAGE KINASE MODULATORS
-
Page 41-42, (2008/06/13)
The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain
Sawyer, J. Scott,Beight, Douglas W.,Britt, Karen S.,Anderson, Bryan D.,Campbell, Robert M.,Goodson Jr., Theodore,Herron, David K.,Li, Hong-Yu,McMillen, William T.,Mort, Nicholas,Parsons, Stephen,Smith, Edward C. R.,Wagner, Jill R.,Yan, Lei,Zhang, Faming,Yingling, Jonathan M.
, p. 3581 - 3584 (2007/10/03)
We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-β type I receptor kinase domain (TβR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both e
